 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234» |
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion, Enrollment change, Trial primary completion date: Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Na (clinicaltrials.gov) - Mar 23, 2016
P=N/A, N=33, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | N=24 --> 33 | Trial primary completion date: Sep 2016 --> Jan 2016
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion, Adverse events: Atripla to Stribild Switch Study to Evaluate Sleep Disturbances (clinicaltrials.gov) - Mar 22, 2016
P4, N=25, Completed, Sponsor: Midtown Medical Center, Tampa, FL
Active, not recruiting --> Completed | N=24 --> 33 | Trial primary completion date: Sep 2016 --> Jan 2016 Active, not recruiting --> Completed
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open, Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Mar 22, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (clinicaltrials.gov) - Mar 18, 2016
P4, N=72, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016 Active, not recruiting --> Completed
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Sleep and Cognition After Atripla to Stribild Switch (clinicaltrials.gov) - Mar 14, 2016
P4, N=30, Recruiting, Sponsor: University of Hawaii
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Jul 2016
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Stribild HIV-2: An Open Label Trial of Stribild for Antiretroviral (ARV)-na (clinicaltrials.gov) - Mar 7, 2016
P4, N=30, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Apr 2015 --> Jul 2016 Recruiting --> Active, not recruiting
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women (clinicaltrials.gov) - Feb 17, 2016
P3, N=400, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: QUAD: HIV Non-Occupational Post-Exposure Prophylaxis (clinicaltrials.gov) - Feb 5, 2016
P4, N=120, Recruiting, Sponsor: Kenneth H. Mayer, MD
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2016
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Jan 17, 2016
P1, N=40, Not yet recruiting, Sponsor: Bayer
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Oct 2016 --> Jan 2018
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: PHI04: Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (clinicaltrials.gov) - Jan 16, 2016
P3, N=30, Active, not recruiting, Sponsor: Duke University
Trial primary completion date: Oct 2016 --> Jan 2018 Recruiting --> Active, not recruiting
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women (clinicaltrials.gov) - Jan 15, 2016
P3, N=400, Not yet recruiting, Sponsor: Gilead Sciences
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Stribild HIV-2: An Open Label Trial of Stribild for Antiretroviral (ARV)-na (clinicaltrials.gov) - Dec 18, 2015
P4, N=30, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Trial primary completion date: May 2016 --> Dec 2016
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (clinicaltrials.gov) - Nov 21, 2015
P4, N=72, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jan 2016
- efavirenz / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=10, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2016 --> Jan 2016 Recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2015
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Sep 22, 2015
P1, N=40, Not yet recruiting, Sponsor: Bayer
- |||| Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Enrollment open, IO biomarker: Renal Integrase Study (clinicaltrials.gov) - Sep 17, 2015
P4, N=60, Recruiting, Sponsor: St Stephens Aids Trust
Recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (clinicaltrials.gov) - Aug 27, 2015
P4, N=72, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment change: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Jul 15, 2015
P2, N=279, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting N=150 --> 279
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial, Adverse events: Atripla to Stribild Switch Study to Evaluate Sleep Disturbances (clinicaltrials.gov) - Jun 22, 2015
P4, N=25, Active, not recruiting, Sponsor: Midtown Medical Center, Tampa, FL
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents (clinicaltrials.gov) - Jun 16, 2015
P2/3, N=50, Active, not recruiting, Sponsor: Gilead Sciences
N=150 --> 279 Trial primary completion date: Jun 2015 --> Oct 2015
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial, HEOR, Cost effectiveness: Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (clinicaltrials.gov) - Jun 12, 2015
P4, N=150, Not yet recruiting, Sponsor: Juan A. Arnaiz
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Jun 11, 2015
P4, N=10, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Jun 2015 --> Oct 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=14, Recruiting, Sponsor: University of California, San Diego
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Na (clinicaltrials.gov) - May 14, 2015
P=N/A, N=24, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Tybost (cobicistat) / Gilead
Trial completion: Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment (clinicaltrials.gov) - Mar 17, 2015
P3, N=106, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: CRUSTRI: Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet (clinicaltrials.gov) - Feb 24, 2015
P1, N=24, Completed, Sponsor: Radboud University
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
New P4 trial, IO biomarker: Renal Integrase Study (clinicaltrials.gov) - Jan 30, 2015
P4, N=60, Not yet recruiting, Sponsor: St Stephens Aids Trust
- ||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Jan 26, 2015
P3, N=439, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Jan 26, 2015
P3, N=438, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (clinicaltrials.gov) - Jan 8, 2015
P4, N=64, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P1 trial: CRUSTRI: Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet (clinicaltrials.gov) - Dec 29, 2014
P1, N=24, Recruiting, Sponsor: Radboud University
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P2 trial: Clinical trial to determinate viral load in seminal fluid in HIV-positive patients without previous treatment Ensayo clinico para medir la carga viral en el semen de pacientes VIH que no han recibido tratamiento antirretroviral previamente (EUDRACT) - Dec 12, 2014
P2, N=36, Ongoing, Sponsor: Fundaci
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents (clinicaltrials.gov) - Dec 6, 2014
P2/3, N=50, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Clinical: STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY) (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=30, Recruiting, Sponsor: Vancouver Infectious Diseases Centre
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Nov 12, 2014
P4, N=10, Recruiting, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial initiation date: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=14, Not yet recruiting, Sponsor: University of California, San Diego
Not yet recruiting --> Recruiting Initiation date: Oct 2014 --> Jan 2015
- |||| Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Nov 5, 2014
P3, N=1500, Active, not recruiting, Sponsor: Gilead Sciences
Initiation date: Oct 2014 --> Jan 2015 Trial primary completion date: Oct 2014 --> Mar 2015
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: Sleep and Cognition After Atripla to Stribild Switch (clinicaltrials.gov) - Nov 5, 2014
P4, N=30, Recruiting, Sponsor: University of Hawaii
- Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Enrollment open, Trial primary completion date: SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers (clinicaltrials.gov) - Nov 5, 2014
P1, N=16, Recruiting, Sponsor: St Stephens Aids Trust
Trial primary completion date: Oct 2014 --> Mar 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> May 2015
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion, Trial primary completion date: Changes in Insulin Resistance in Healthy Volunteers on STRIBILD (clinicaltrials.gov) - Nov 5, 2014
P1, N=30, Completed, Sponsor: Technische Universit
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> May 2015 Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: Stribild HIV-2: An Open Label Trial of Stribild for Antiretroviral (ARV)-na (clinicaltrials.gov) - Sep 30, 2014
P4, N=30, Recruiting, Sponsor: University of Washington
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014 Not yet recruiting --> Recruiting
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Clinical: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=14, Not yet recruiting, Sponsor: University of California, San Diego
- ||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Sep 29, 2014
P3, N=708, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- efavirenz / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=10, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Jan 2014 | Trial primary completion date: May 2014 --> May 2015
- ||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (clinicaltrials.gov) - Sep 28, 2014
P4, N=64, Not yet recruiting, Sponsor: Gilead Sciences
- ||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Sep 16, 2014
P3, N=707, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Jan 2014 | Trial primary completion date: May 2014 --> May 2015 Active, not recruiting --> Completed
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment change, Trial primary completion date: Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Na (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=24, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed N=15 --> 24 | Trial primary completion date: Dec 2014 --> Sep 2016
- ribavirin / Generic mfg.
New P4 trial: Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study (clinicaltrials.gov) - Aug 21, 2014
P4, N=10, Recruiting, Sponsor: Saint Michael's Medical Center
- | Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
New P1 trial: SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers (clinicaltrials.gov) - Aug 19, 2014
P1, N=16, Not yet recruiting, Sponsor: St Stephens Aids Trust
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P1 trial: Changes in Insulin Resistance in Healthy Volunteers on STRIBILD (clinicaltrials.gov) - Jul 30, 2014
P1, N=30, Recruiting, Sponsor: Technische Universit